Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 6/20 | 0.54 |
| ▸ | DRD2 | P14416 | 5/20 | 0.54 |
| ▸ | DRD1 | P21728 | 3/20 | 0.54 |
| ▸ | DRD5 | P21918 | 3/20 | 0.54 |
| ▸ | DRD4 | P21917 | 4/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400914 | 0.87 | DRD2 (0.52) | DRD3DRD2DRD4HTR1AHTR2A | |
| SCHEMBL4240910 | 0.87 | MAPT (0.42) | DRD3DRD2DRD1DRD5DRD4 | |
| SCHEMBL4245287 | 0.87 | MAPT (0.42) | DRD3DRD2DRD1DRD5DRD4 | |
| SCHEMBL4248577 | 0.87 | MAPT (0.45) | DRD3DRD2DRD1DRD5DRD4 | |
| SCHEMBL4252387 | 0.86 | SMN1; SMN2 (0.53) | DRD4KDM4EPPARGPPARAMAPT | |
| SCHEMBL4245098 | 0.85 | OPRM1 (0.45) | DRD3DRD2DRD1DRD5DRD4 | |
| SCHEMBL4241368 | 0.85 | OPRM1 (0.49) | DRD3DRD2DRD4HTR1AHTR2A | |
| SCHEMBL4248465 | 0.85 | SMO (0.46) | DRD3DRD2DRD1DRD5DRD4 | |
| SCHEMBL4391668 | 0.84 | MAPT (0.54) | DRD3DRD2DRD4HTR1AHTR2A | |
| SCHEMBL4252187 | 0.84 | KDM4E (0.52) | DRD3DRD2DRD4HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | claimed |
| CN-101490010-A | Compounds and compositions as ITPKB inhibitors | IRM LLC (VG) | 2009-07-22 | — | — | CN | claimed |
| EP-2057124-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM, LLC (BM) | 2009-05-13 | — | — | EP | claimed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | claimed |
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | disclosed |
| CN-101490010-A | Compounds and compositions as ITPKB inhibitors | IRM LLC (VG) | 2009-07-22 | — | — | CN | disclosed |
| EP-2057124-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM, LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | DRD3 4698/4885DRD2 4806/4885DRD1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.